Alnylam stops development of drug due to patient deaths in trial

(Reuters) - Alnylam Pharmaceuticals Inc said on Wednesday it would halt development of an experimental therapy for a rare genetic condition that can cause heart failure, when a late-stage study showed that patients given the drug were more likely to die than patients treated with a placebo.